为什么状态试验失败了:错误的药物还是错误的试验?
1City St George's, University of London, School of Health and Medical Sciences, Neurosciences Clinical Academic Group, Cranmer Terrace, London SW17 0RE, UK.
Epilepsy & behavior : E&B
|September 1, 2024
概括
尽管经过数十年的研究,临床试验结果对于状态仍然很差. 该审查审查了试验失败的原因,并建议改善试验设计和监管框架,以获得更好的结果.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 的研究研究.
背景情况:
- 在过去的20年里,状态 (SE) 研究的兴趣有所增加.
- 尽管如此,患者的治疗结果并没有得到改善,一些备受目的试验也失败了.
- 这些故障的原因是多方面的,需要仔细考虑.
研究的目的:
- 讨论状态的临床试验失败背后的各种原因.
- 在更广泛的科学背景下审查解释试验结果的重要性.
- 检查试验设计,监管框架和人工智能使用的潜在改进.
主要方法:
- 审查最近的精心设计,充足的动力研究在已建立的SE.
- 对耐火和超耐火SE.研究的分析.
- 考虑从其他疾病领域吸取的经验教训,包括COVID-19 RECOVERY试验.
主要成果:
- 虽然已建立的SE试验未能达到主要终点,但仍在影响临床实践.
- 耐火性和超耐火性SE的试验尚未取得成功的结果.
- 不成功的SE试验会带来巨大的财务和人力成本.
结论:
- 解释试验结果需要考虑更广泛的文献,安全性和实际方面.
- 有必要审查监管框架,并适应SE的试验设计.
- 人工智能工具可能为未来的试验优化提供潜力.
相关概念视频
Arteries of the Lower Limbs
181
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
Antiepileptic Drugs: Potassium Channel Activators
150
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
150
Electroconvulsive Therapy
29
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
Seizures: Classification
309
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
309
Antiepileptic Drugs: Glutamate Antagonists
300
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
300
Depolarizing Blockers: Pharmocokinetics
315
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
315


